Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Takeda Pharmaceutical Company Limited

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Takeda Named Global Top Employer for Fourth Consecutive Year
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving... 
Tickers TAK
From Business Wire News Releases
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on the progress of its continued transformation and growth today at the virtual 39th Annual J.P. Morgan... 
Tickers TAK
From Business Wire News Releases
Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20... 
Tickers TAK
From Business Wire News Releases
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of non-core prescription pharmaceutical products sold in... 
Tickers TAK
From Business Wire News Releases
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG®... 
Tickers TAK
From Business Wire News Releases
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the company’s New Drug... 
Tickers TAK
From Business Wire News Releases
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to... 
Tickers TAK
From Business Wire News Releases
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema 
Tickers TAK
From Business Wire News Releases
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
Takeda today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting. 
Tickers TAK
From Business Wire News Releases
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
New Phase 3 Data Show TAK-620, an Investigational Drug for the Treatment of Transplant Recipients with CMV Infections, Meets Primary Endpoint 
Tickers TAK
From Business Wire News Releases
Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated], a web-based... 
Tickers TAK
From Business Wire News Releases
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”)... 
Tickers TAK
From Business Wire News Releases
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
Final Results from Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option 
Tickers TAK
From Business Wire News Releases
Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced it will present nine company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting, being held... 
Tickers TAK
From Business Wire News Releases
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting,... 
Tickers TAK
From Business Wire News Releases
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2020 (period ended September 30, 2020). 
Tickers TAK
From Business Wire News Releases
Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), announced today that it will import and distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, starting in the first... 
Tickers TAK
From Business Wire News Releases
Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America (THSNA), highlighting Takeda’s commitment... 
Tickers TAK
From Business Wire News Releases
BioLife Plasma Services Announces Opening of First Plasma Collection Center in Nebraska
BioLife Plasma Services announces the opening of the first plasma collection center in Nebraska. 
Tickers TAK
From Business Wire News Releases
Takeda Accelerates Digital Transformation with Accenture and AWS
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”), Accenture (NYSE: ACN) and Amazon Web Services, Inc. (AWS) have entered into a five-year strategic agreement to accelerate... 
Tickers ACN TAK
From Business Wire News Releases
Safety and Efficacy of Subcutaneous Entyvio® (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis
Safety and Efficacy of SC Entyvio (Vedolizumab) Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active UC 
Tickers TAK
From Business Wire News Releases
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Takeda and Arrowhead announced a collaboration and licensing agreement to develop ARO-AAT, a Ph. 2 investigational RNAi therapy to treat AATLD. 
Tickers ARWR TAK
From Business Wire News Releases
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical... 
Tickers TAK
From Business Wire News Releases
Takeda to Divest TachoSil® to Corza Health for €350 Million
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest its TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health,... 
Tickers TAK
From Business Wire News Releases
Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs
Takeda opened a new R&D cell therapy manufacturing facility, which will accelerate Takeda's efforts to develop next-generation cell therapies. 
Tickers TAK
From Business Wire News Releases
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3 TOURMALINE-MM2 trial evaluating the addition of NINLARO™ (ixazomib) to lenalidomide and... 
Tickers TAK
From Business Wire News Releases
Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products... 
Tickers TAK
From Business Wire News Releases
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. announced positive topline results from the Phase 2 ELEKTRA study of soticlestat. 
Tickers OVID TAK
From Business Wire News Releases
National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease
A new series of public service announcements featuring actress Alex Borstein aims to educate the public about the symptoms of von Willebrand disease. 
Tickers TAK
From Business Wire News Releases
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK),... 
Tickers NVAX TAK
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.